| 1 |
Review Caenohabditis elegans in Parkinson's disease drug discovery: addressing an unmet medical need. 2008
Nass R, Merchant KM, Ryan T. · Department of Pharmacology and Toxicology, Center for Environmental Health, and Stark Neuroscience Research Institute, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA. · Mol Interv. · Pubmed #19144901 No free full text.
Abstract: It has been over forty years since dopamine neuron degeneration in the substantia nigra and Lewy body formation within surviving cells were described as the pathological hallmarks of Parkinson's disease (PD). Although research in the intervening decades particularly in the last twenty-five years has yielded a variety of robust animal models and invaluable mechanistic insights into PD-associated neuronal dysfunction and cell death, therapeutic agents have not been forthcoming to alter the course of PD. Recently, the screening of experimental therapeutics for PD has been pursued through the use of genetically tractable models, such as the nematode Caenorhabditis elegans. This simple worm remarkably recapitulates the basic cellular and molecular pathways associated with PD, is amenable to facile genetic methods, and through the use of high-throughput screening technologies, provides powerful new opportunities for the in vivo identification of therapeutic targets. In this review we briefly describe the utility that the C. elegans model system may have for PD drug discovery.
|
| 2 |
Review Neuroreplacement, growth factor, and small molecule neurotrophic approaches for treating Parkinson's disease. 2007
O'Neill MJ, Messenger MJ, Lakics V, Murray TK, Karran EH, Szekeres PG, Nisenbaum ES, Merchant KM. · Eli Lilly and Co. Ltd., Lilly Research Centre, Erl Wood Manor, Windlesham Surrey GU20 6PH, United Kingdom. · Int Rev Neurobiol. · Pubmed #17178475 No free full text.
This publication has no abstract.
|